B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.

Published

Journal Article

The B cell arm of the immune response becomes activated soon after HIV-1 transmission, yet the initial antibody response does not control HIV-1 replication, and it takes months for neutralizing antibodies to develop against the autologous virus. Antibodies that can be broadly protective are made only in a minority of subjects and take years to develop--too late to affect the course of disease. New studies of the earliest stages of HIV-1 infection, new techniques to probe the human B cell repertoire, the modest degree of efficacy in a vaccine trial and new studies of human monoclonal antibodies that represent the types of immune responses an HIV-1 vaccine should induce are collectively illuminating paths that a successful HIV-1 vaccine might take.

Full Text

Duke Authors

Cited Authors

  • Haynes, BF; Moody, MA; Liao, H-X; Verkoczy, L; Tomaras, GD

Published Date

  • February 2011

Published In

Volume / Issue

  • 17 / 2

Start / End Page

  • 108 - 116

PubMed ID

  • 21112250

Pubmed Central ID

  • 21112250

Electronic International Standard Serial Number (EISSN)

  • 1471-499X

Digital Object Identifier (DOI)

  • 10.1016/j.molmed.2010.10.008

Language

  • eng

Conference Location

  • England